Profile data is unavailable for this security.
About the company
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Its segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. It also provides testing and laboratory services, mainly to the dental and pharmaceutical industries. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services quality control products. It has manufacturing operations in the United States and Europe.
- Revenue in USD (TTM)223.71m
- Net income in USD-250.31m
- Incorporated1982
- Employees736.00
- LocationMesa Laboratories Inc12100 W 6th AveLAKEWOOD 80228-1252United StatesUSA
- Phone+1 (303) 987-8000
- Fax+1 (303) 987-8989
- Websitehttps://mesalabs.com
More ▼
Mergers & acquisitions
| Acquired company | MLAB:NSQ since announced | Transaction value |
|---|---|---|
| SAL Schiffahrtskontor Altes Land GmbH & Co KG | 26.73% | 89.33m |
| gke-GmbH-Sterilization Indicators Business | 26.73% | -- |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacific Biosciences of California Inc | 188.87m | -400.38m | 497.37m | 796.00 | -- | 1.01 | -- | 2.63 | -1.50 | -1.50 | 0.7099 | 1.81 | 0.1125 | 2.05 | 6.69 | 237,275.10 | -23.85 | -16.19 | -26.63 | -17.81 | 26.01 | 37.35 | -211.99 | -136.21 | 7.14 | -22.46 | 0.6444 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Surmodics Inc | 120.82m | -1.40m | 555.73m | 376.00 | -- | 4.74 | 75.99 | 4.60 | -0.0955 | -0.0955 | 8.55 | 8.28 | 0.6597 | 2.09 | 5.64 | 321,332.40 | -0.7638 | -1.85 | -0.8909 | -2.18 | 74.02 | 82.93 | -1.16 | -2.98 | 3.22 | -4.46 | 0.1999 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Quanterix Corp | 129.33m | -39.71m | 558.03m | 441.00 | -- | 1.66 | -- | 4.31 | -1.04 | -1.04 | 3.40 | 8.77 | 0.3078 | 2.37 | 4.60 | 293,265.30 | -9.45 | -15.96 | -10.30 | -17.66 | 57.42 | 52.79 | -30.71 | -53.79 | 8.99 | -- | 0.00 | -- | 15.96 | 26.60 | 66.56 | -- | 20.07 | -- |
| Paragon 28 Inc | 235.44m | -59.07m | 573.67m | 430.00 | -- | 3.91 | -- | 2.44 | -0.7132 | -0.7132 | 2.84 | 1.76 | 0.7703 | 0.6049 | 6.63 | 547,539.60 | -19.33 | -- | -23.48 | -- | 76.67 | -- | -25.09 | -- | 1.70 | -5.30 | 0.4295 | -- | 19.30 | -- | 28.94 | -- | -- | -- |
| Iradimed Corp | 69.48m | 18.64m | 607.90m | 148.00 | 32.80 | 7.63 | 31.23 | 8.75 | 1.46 | 1.46 | 5.45 | 6.29 | 0.8109 | 1.55 | 6.03 | 469,485.30 | 21.76 | 13.16 | 23.85 | 14.58 | 77.21 | 76.55 | 26.83 | 21.46 | 8.25 | 144.05 | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| Orthofix Medical Inc | 771.65m | -120.49m | 608.35m | 1.63k | -- | 1.13 | -- | 0.7884 | -3.21 | -3.21 | 20.55 | 14.35 | 0.8654 | 1.17 | 6.49 | 472,245.40 | -13.51 | -8.88 | -16.22 | -10.96 | 67.18 | 72.37 | -15.62 | -9.28 | 1.13 | -4.94 | 0.2005 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| AxoGen Inc | 173.48m | -16.54m | 617.12m | 426.00 | -- | 6.45 | -- | 3.56 | -0.3829 | -0.3829 | 4.01 | 2.18 | 0.9117 | 1.62 | 7.43 | 407,237.10 | -8.69 | -13.92 | -9.93 | -15.84 | 76.98 | 79.74 | -9.53 | -20.28 | 2.32 | -2.94 | 0.3297 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Simulations Plus Inc | 66.98m | 9.65m | 624.84m | 192.00 | 65.88 | 3.45 | 44.19 | 9.33 | 0.474 | 0.474 | 3.29 | 9.04 | 0.3603 | -- | 5.57 | 348,843.80 | 5.19 | 7.20 | 5.49 | 7.61 | 72.53 | 77.61 | 14.40 | 21.29 | -- | -- | 0.00 | 45.70 | 10.52 | 14.96 | -20.20 | 6.02 | 12.91 | 0.8548 |
| Jin Medical International Ltd | 20.13m | 2.91m | 638.71m | 245.00 | 218.88 | 24.34 | 209.57 | 31.74 | 0.0186 | 0.0186 | 0.1292 | 0.1676 | 0.5576 | 2.38 | 4.22 | 82,143.59 | 7.80 | 12.81 | 11.27 | 20.92 | 34.73 | 33.58 | 13.99 | 14.60 | 2.27 | -- | 0.2702 | 0.00 | 3.29 | -1.07 | 6.34 | -4.80 | -9.50 | -- |
| SI-Bone Inc | 150.71m | -40.85m | 641.67m | 344.00 | -- | 3.88 | -- | 4.26 | -1.00 | -1.00 | 3.70 | 3.97 | 0.6586 | 1.54 | 6.67 | 438,107.60 | -17.85 | -27.88 | -19.57 | -30.94 | 77.69 | 85.03 | -27.10 | -51.09 | 8.12 | -- | 0.18 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
| Cytek Biosciences Inc | 197.71m | -17.56m | 669.36m | 645.00 | -- | 1.72 | -- | 3.39 | -0.1327 | -0.1327 | 1.49 | 2.96 | 0.392 | 1.54 | 4.19 | 292,470.40 | -3.48 | -- | -3.89 | -- | 54.97 | -- | -8.88 | -- | 6.38 | -- | 0.0083 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Mesa Laboratories Inc | 223.71m | -250.31m | 695.46m | 736.00 | -- | 4.61 | -- | 3.11 | -46.43 | -46.43 | 41.43 | 27.87 | 0.4131 | 2.51 | 6.29 | 303,956.50 | -46.23 | -9.20 | -50.62 | -9.88 | 62.27 | 60.60 | -111.89 | -28.33 | 1.37 | 1.33 | 0.5848 | -- | -1.32 | 15.95 | -27,438.28 | -- | 15.26 | 0.00 |
| Orthopediatrics Corp | 175.07m | -25.12m | 695.92m | 247.00 | -- | 1.87 | -- | 3.98 | -1.10 | -1.10 | 7.65 | 15.33 | 0.4045 | 0.4286 | 4.61 | 708,793.50 | -5.80 | -5.40 | -6.43 | -5.93 | 74.62 | 75.09 | -14.35 | -15.92 | 1.96 | -44.23 | 0.0261 | -- | 21.62 | 20.91 | -1,767.25 | -- | 28.29 | -- |
| Standard Biotools Inc | 136.30m | -164.66m | 746.02m | 534.00 | -- | 1.46 | -- | 5.47 | -0.9018 | -0.9018 | 0.6606 | 1.37 | 0.2561 | 2.25 | 5.73 | 255,243.50 | -22.29 | -28.17 | -26.55 | -33.60 | 46.67 | 51.58 | -87.05 | -74.85 | 3.53 | -- | 0.0974 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
| Alphatec Holdings Inc | 540.28m | -180.91m | 846.97m | 839.00 | -- | 50.40 | -- | 1.57 | -1.34 | -1.34 | 4.00 | 0.2847 | 0.7736 | 1.13 | 7.30 | 643,959.50 | -25.90 | -30.97 | -33.24 | -39.47 | 69.44 | 66.02 | -33.48 | -46.22 | 1.21 | -4.59 | 0.9273 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| Castle Biosciences Inc | 287.59m | -3.10m | 872.88m | 610.00 | -- | 2.06 | 87.40 | 3.04 | -0.1346 | -0.1346 | 10.45 | 15.30 | 0.6302 | 7.38 | 7.44 | 471,457.40 | -0.6791 | -9.43 | -0.7383 | -10.17 | 81.86 | 80.58 | -1.08 | -28.46 | 7.92 | -- | 0.0238 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
Data as of Sep 20 2024. Currency figures normalised to Mesa Laboratories Inc's reporting currency: US Dollar USD
56.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 738.12k | 13.68% |
| Conestoga Capital Advisors LLCas of 30 Jun 2024 | 572.62k | 10.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 359.45k | 6.66% |
| Royce & Associates LPas of 31 Mar 2024 | 283.74k | 5.26% |
| Ranger Investment Management LPas of 31 Mar 2024 | 229.15k | 4.25% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 201.73k | 3.74% |
| Atlanta Capital Management Co. LLCas of 31 Mar 2024 | 194.95k | 3.61% |
| Geneva Capital Management LLCas of 31 Mar 2024 | 194.33k | 3.60% |
| Eagle Asset Management, Inc.as of 31 Mar 2024 | 145.76k | 2.70% |
| Boone Capital Management LLCas of 31 Mar 2024 | 133.39k | 2.47% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
